CompletedPHASE1, PHASE2NCT03250325
Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma
Studying Synovial sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Takara Bio Inc.
- Principal Investigator
- Masanobu KimuraTakara Bio Inc.
- Intervention
- TBI-1301(biological)
- Enrollment
- 8 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2022
Study locations (5)
- Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan
- Mie University Hospital, Tsu, Mie-ken, Japan
- National Hospital Organization Osaka National Hospital, Osaka, Osaka, Japan
- National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
- Kyushu University Hospital, Fukuoka, Japan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03250325 on ClinicalTrials.govOther trials for Synovial sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07174427Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial SarcomaTakara Bio Inc.
- RECRUITINGPHASE1NCT06946225ACTengine® IMA203 Combined With mRNA-4203Immatics US, Inc.
- RECRUITINGNCT05910307Synovial Sarcoma Registry / Biospecimen RepositoryChildren's Hospital of Philadelphia